Oncology News | pharmaphorum

News

EU clears path for Pfizer’s takeover of Seagen

Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t

News

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to

News

Lilly makes another ADC play, buying Mablink

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has bec

News

Seagen wins future royalties in Enhertu patent dispute

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in da

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

News

Nucleus RadioPharma raises $56m in first round financing

There’s a new kid on the block in the fast-growing radiopharmaceuticals category, as Nucleus RadioPharma chalks up an oversubscribed Series A that raised $56 million that

EU clears path for Pfizer’s takeover of Seagen

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Lilly makes another ADC play, buying Mablink

Seagen wins future royalties in Enhertu patent dispute

Roche sticks with molecular glue, partnering Monte Rosa

Nucleus RadioPharma raises $56m in first round financing

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks